Eevia Health
Eevia Health Plc received a multiple sales order for extract products with combined value of 347 KSEK / 31 KEUR
The customers are existing customers located in Slovenia and Taiwan, who order regularly. The products are Eevia's branded ingredient Feno-Myrtillus® 25 Organic, Feno-Myrtillus® 5 Organic, Fenoprolic® Full Spectrum (a pine bark extract) and a Chaga powder. The sales value to Eevia of the new orders is kEUR 31 and the products ordered are in stock.
The order is expected to be followed by further repeat orders in the future.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.
Datum | 2024-01-09, kl 13:37 |
Källa | Cision |